DRG Market Assessment reports
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Parkinson’s Disease – Access & Reimbursement – Access & Reimbursement – Parkinson’s Disease (US)
Since 2015, eight new brands have launched into the highly generic U.S. Parkinson’s disease (PD) therapy market, and six more are expected to launch soon. Chronic polypharmacy and progressive…
Parkinson’s Disease | Unmet Need | Adjunctive Therapies for Motor Response Fluctuations | US/EU | 2021
Although motor fluctuations in Parkinson’s disease (PD) can be managed effectively in early stages of the disease, today’s treatment paradigm is suboptimal owing to considerable pill burden, a…